Eisai Launches New Dry Syrup Formulation of Aricept in Japan

Eisai has launched a new dry syrup formulation of its Alzheimer's disease treatment Aricept (donepezil hydrochloride) in Japan.
Jun 25, 2013
By PharmTech Editors

Eisai has launched a new dry syrup formulation of its Alzheimer's disease treatment Aricept (donepezil hydrochloride) in Japan. Aricept dry syrup 1% is a suspension formulation that allows the dosage to be adjusted within the range of approved dosage amounts at the time of administration according to individual patient needs. The dry syrup can be taken with water in the same way as the existing fine granules formulation but is only half as bulky, making it easier for patients who have difficulty swallowing the existing formulation.

Aricept is indicated for the treatment of mild to severe Alzheimer's disease. A wide range of formulations are available, such as tablets, orally disintegrating tablets, fine granules and an oral jelly formulation to meet the various needs of patients and caregivers. Eisai's new formulation of Aricept is the first dry syrup to have been approved for the treatment of Alzheimer's disease according to the company’s press release. Eisai received manufacturing and marketing authorization for the new formulation in February 2013. The dry syrup formulation provides an alternative for patients with dysphagia or other difficulties in administering the drug.